Eyewire+Biogen to Acquire Apellis Pharmaceuticals in $5.6 Billion Deal

Biogen acquires Apellis Pharmaceuticals for $5.6 billion ($41/share cash plus performance CVR). Deal closes Q2 2026 pending regulatory approval. Combined Apellis revenues reached $689 million in 2025, led by Syfovre at $587 million.

Drug Status

Syfovre (pegcetacoplan) remains the first and only FDA-approved geographic atrophy therapy in the U.S. and Australia. European approval was unsuccessful. 5-year GALE extension data shows Syfovre delayed GA lesion progression by 1.5 years in nonsubfoveal patients versus sham. Izervay (avacincaptad pegol) remains its sole FDA-approved competitor.

What Changes / What Stays the Same

• Stays the same: FDA approval, current supply chain, U.S. prescribing access, and Sobi’s ex-U.S. Empaveli rights
• Stays the same: Syfovre clinical data and treatment protocols
• Changes: Corporate ownership and commercial infrastructure absorb into Biogen post-close
• Changes: Long-term pricing, contracting, and payer negotiations will reflect Biogen’s portfolio strategy

Watch For

• Biogen payer contracting changes affecting Syfovre reimbursement post-Q2 2026 close
• European resubmission strategy under new ownership
• Whether Biogen pursues label expansion given the 5-year GALE data
• Izervay’s competitive response as a single major pharma entity consolidates the GA market.

Related Reading